Bicycle Therapeutics plc (FRA:50BA)

Market Cap	447.48M
Revenue (ttm)	24.15M
Net Income (ttm)	-213.64M
Shares Out	n/a
EPS (ttm)	-3.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	17
Open	6.05
Previous Close	6.00
Day's Range	6.05 - 6.10
52-Week Range	5.05 - 20.00
Beta	n/a
RSI	56.75
Earnings Date	Feb 20, 2026

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 305
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 50BA

Financial Performance

In 2024, Bicycle Therapeutics's revenue was $35.28 million, an increase of 30.76% compared to the previous year's $26.98 million. Losses were -$169.03 million, -6.44% less than in 2023.

Financial numbers in USD